logo
State lawmakers to Congress: Don't stop us from regulating AI

State lawmakers to Congress: Don't stop us from regulating AI

Washington Post03-06-2025
Happy Tuesday! You want the truth, but can you handle this many Truths? Send news tips to: will.oremus@washpost.com
State lawmakers to Congress: Don't stop us from regulating AI.
As the Senate takes up President Donald Trump's massive tax and immigration bill this week, state lawmakers from both parties are calling on Congress to remove a provision that would place a 10-year moratorium on state-level AI regulations.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Yahoo

time5 minutes ago

  • Yahoo

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TD Cowen Lowers Clear Channel Outdoor (CCO) PT to $1.60 Despite Strong Q2 Performance
TD Cowen Lowers Clear Channel Outdoor (CCO) PT to $1.60 Despite Strong Q2 Performance

Yahoo

time5 minutes ago

  • Yahoo

TD Cowen Lowers Clear Channel Outdoor (CCO) PT to $1.60 Despite Strong Q2 Performance

Clear Channel Outdoor Holdings Inc. (NYSE:CCO) is one of the most promising penny stocks under $5. Earlier on July 22, TD Cowen lowered the firm's price target on Clear Channel Outdoor to $1.60 from $1.70, while keeping a Buy rating on the shares. This sentiment by the firm came ahead of the company's Q2 2025 results, with expectations for higher consolidated revenue and outperformance in the Airport segment to offset softness in the America segment. Later in August, Clear Channel Outdoor Holdings' consolidated revenue came out to be $402.8 million in Q2, which was a 7% improvement year-over-year. The America segment recorded its highest-ever second-quarter revenue at $303.1 million due to robust digital and local sales. The Airports segment also performed strongly, with a 15.6% increase in revenue, reaching $99.7 million, powered by growth in both national and local sales channels. A busy street corner, with strategically placed advertisements to attract customers. However, the company's static advertising segment continues to lag behind digital growth. National sales in the America segment were also down 1% on a comparable basis. The company is still in the process of selling its business in Spain as well. Clear Channel Outdoor Holdings Inc. (NYSE:CCO) is an out-of-home advertising company in the US and Singapore. The company operates in 2 segments: America and Airports. While we acknowledge the potential of CCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump Says Zelenskyy Can End Russia-Ukraine War ‘Almost Immediately' Ahead of Planned Talks
Trump Says Zelenskyy Can End Russia-Ukraine War ‘Almost Immediately' Ahead of Planned Talks

Epoch Times

time8 minutes ago

  • Epoch Times

Trump Says Zelenskyy Can End Russia-Ukraine War ‘Almost Immediately' Ahead of Planned Talks

President Donald Trump said on Sunday that Ukrainian President Volodymyr Zelenskyy could choose to end the Russia-Ukraine war 'almost immediately,' ahead of their planned meeting on Aug. 18. The two leaders are scheduled to meet at the White House on Aug. 18, as Trump seeks to mediate a deal to end the Russia-Ukraine war following his Aug. 15 summit with Russian President Vladimir Putin.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store